QC
BMRN icon

Quent Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quent Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2K Sell
266
-103
-28% -$5.64K ﹤0.01% 1137
2026
Q1 		$20.8K Buy
369
+45
+14% +$2.62K ﹤0.01% 982
2025
Q4 		$19.3K Sell
324
-202
-38% -$11K ﹤0.01% 1001
2025
Q3 		$28.5K Buy
+526
New +$30.1K ﹤0.01% 759
2025
Q2 		– Sell
-189
Closed -$13.4K – 400
2025
Q1 		$13.4K Buy
189
+33
+21% +$2.22K ﹤0.01% 856
2024
Q4 		$10.3K Sell
156
-100
-39% -$6.7K ﹤0.01% 931
2024
Q3 		$18K Sell
256
-135
-35% -$11.3K ﹤0.01% 905
2024
Q2 		$32.2K Buy
391
+145
+59% +$12.1K ﹤0.01% 743
2024
Q1 		$21.5K Sell
246
-112
-31% -$10K ﹤0.01% 863
2023
Q4 		$34.5K Buy
358
+23
+7% +$2.04K ﹤0.01% 706
2023
Q3 		$29.6K Sell
335
-1,223
-78% -$109K ﹤0.01% 707
2023
Q2 		$135K Buy
1,558
+23
+1% +$2.16K 0.02% 358
2023
Q1 		$147K Buy
1,535
+1,374
+853% +$142K 0.03% 337
2022
Q4 		$16.7K Hold
161
– – ﹤0.01% 804
2022
Q3 		$14K Buy
161
+12
+8% +$1.07K ﹤0.01% 799
2022
Q2 		$12K Hold
149
– – ﹤0.01% 793
2022
Q1 		$11K Buy
149
+30
+25% +$2.51K ﹤0.01% 887
2021
Q4 		$11K Buy
+119
New +$9.82K ﹤0.01% 803

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quent Capital's BMRN Position: Q2 2026 in Review

Quent Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 28% in Q2 2026, selling an estimated $5.64K and leaving 266 shares worth $15.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Quent Capital first reported a position in BMRN in Q4 2021 and has held it in 18 quarters since. The position peaked at $147K in Q1 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Quent Capital held 266 shares of BioMarin Pharmaceuticals worth $15.2K as of Q2 2026.
  • Quent Capital sold 103 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5.64K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1137 holding.
  • Quent Capital first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's BioMarin Pharmaceuticals position peaked at $147K in Q1 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.